The laboratory of James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, received the 2018 Vaccine Industry Excellence Award for Best Academic Research Team at the 18th World Vaccine Congress in Washington, DC, this week.

Vanderbilt investigators have discovered that cancer treatment induces an “idling” state for cells, which could promote resistance to treatment.

Treatment of anemia caused by chronic kidney disease or other diseases often requires repeated — and costly — injections or infusions of an artificial form of the hormone erythropoietin (EPO), which stimulates production of red blood cells.

Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.

The Vanderbilt Institute of Chemical Biology (VICB) will hold a Founders’ Celebration mini-symposium on March 28 to acknowledge the contributions of its founders, Lawrence Marnett, PhD, and Ned Porter, PhD, and to celebrate 15-plus years of success as a trans-institutional scientific incubator.

MCL-1 is a member of the BCL-2 family of proteins important for blocking apoptosis, or programmed cell death. Many types of cancer cells escape the body’s effort to kill them by overexpressing MCL-1.